High-flying Pfizer may disappoint on Comirnaty and Paxlovid sales in Q1, analyst warns

Pfizer’s BioNTech-partnered COVID-19 vaccine Comirnaty and its antiviral pill Paxlovid are destined to reap many billions in 2022, but the company’s first-quarter pandemic haul may come in lighter than previously thought, one group of analysts predicts.